- Home
- CANF vs MTEK Comparison
CANF vs MTEK Comparison
Compare CANF & MTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- MTEK
- Stock Information
- Founded
- CANF 1994
- MTEK 2008
- Country
- CANF Israel
- MTEK Israel
- Employees
- CANF N/A
- MTEK N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- MTEK
- Sector
- CANF Health Care
- MTEK
- Exchange
- CANF Nasdaq
- MTEK Nasdaq
- Market Cap
- CANF 14.8M
- MTEK N/A
- IPO Year
- CANF N/A
- MTEK 2022
- Fundamental
- Price
- CANF $1.03
- MTEK $3.19
- Analyst Decision
- CANF Strong Buy
- MTEK
- Analyst Count
- CANF 2
- MTEK 0
- Target Price
- CANF $14.00
- MTEK N/A
- AVG Volume (30 Days)
- CANF 145.4K
- MTEK 174.1K
- Earning Date
- CANF 08-29-2025
- MTEK 08-27-2025
- Dividend Yield
- CANF N/A
- MTEK N/A
- EPS Growth
- CANF N/A
- MTEK N/A
- EPS
- CANF N/A
- MTEK N/A
- Revenue
- CANF $674,000.00
- MTEK $6,078,953.00
- Revenue This Year
- CANF $461.72
- MTEK N/A
- Revenue Next Year
- CANF N/A
- MTEK N/A
- P/E Ratio
- CANF N/A
- MTEK N/A
- Revenue Growth
- CANF N/A
- MTEK 50.80
- 52 Week Low
- CANF $0.98
- MTEK $1.45
- 52 Week High
- CANF $4.69
- MTEK $6.47
- Technical
- Relative Strength Index (RSI)
- CANF 40.76
- MTEK 62.59
- Support Level
- CANF $0.99
- MTEK $2.65
- Resistance Level
- CANF $1.09
- MTEK $3.44
- Average True Range (ATR)
- CANF 0.04
- MTEK 0.45
- MACD
- CANF -0.00
- MTEK 0.02
- Stochastic Oscillator
- CANF 22.22
- MTEK 57.47
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).